BSE filing, BSE: 544738. Summary written from the filing by ALFA Finder's alert engine.
Speciality Medicines Ltd: key numbers
- Share price
- ₹140.00
- Market cap
- ₹123.0 Cr
- Revenue (annual)
- ₹75.29 Cr
- Net profit (annual)
- ₹13.03 Cr
- P/E (TTM)
- 9.4×Sector 45.9×
- Promoter holding
- 43.43%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Speciality Medicines Ltd
All →Speciality Medicines Other Announcement
Speciality Medicines Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited conducted its 5th Annual General Meeting on September 28, 2026. Shareholders considered the adoption of FY26 audited financial statements and the re-appointment of Director Sumit Goyani.
Speciality Medicines Annual Report
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.
Speciality Medicines Business Update
Speciality Medicines Limited received regulatory approval for two new products, Olanzapine and Diazepam tablets, in the Ethiopian market, strengthening its international export portfolio.
Speciality Medicines Other Announcement
Speciality Medicines Limited has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency to enhance its investor relations and communication efforts.
Other regulatory approval announcements
All →Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.
Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.